glp·helper
glphelper.com/mounjaro/california/palm-springs
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Palm Springs, CA

Verified Mounjaro providers in Palm Springs, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Mounjaro weight loss →trial-anchored estimate
city providers
31
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
32 of 32 shown

Find a Mounjaro provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /mounjaro/california/{city}
§ 03Getting Mounjaro in Palm Springs
32 providers · Palm Springs, CA

How to get Mounjaro in Palm Springs.

32 GLP-1 prescribers and 6 local resource types are on record for Palm Springs, plus 3 nearby towns in the directory.

Prescribers in Palm Springs
32 prescribers
32 GLP-1 prescribers in Palm Springs, most listed as Family Medicine (14), Internal Medicine (10) and Internal Medicine, Endocrinology, Diabetes & Metabolism (4). Any California-licensed physician, nurse practitioner, or PA can prescribe Mounjaro, over video or in person. The nearest towns on record are Beaumont (24 providers), Moreno Valley (29 providers) and Perris (18 providers).
Around the prescription in Palm Springs
6 listed nearby
18 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 5 physiotherapists and 10 places to move are on record near Palm Springs.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Palm Springs

Palm Springs, California has a population of 44,575 people. The adult obesity rate in Palm Springs is an age-adjusted estimate of 35.6%, 6.5 percentage points above the California state rate of 29.1%. Diagnosed diabetes reaches 9.8% of adults in Palm Springs. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 21.8% of adults in Palm Springs.

of Palm Springs adults have obesity
35.6%
diagnosed diabetes
9.8%
no regular physical activity
21.8%

Age-adjusted estimates for Palm Springs, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossweight regain after stopping
§ 05Support around Mounjaro in Palm Springs
6 gyms

The prescription is one part. Here is the rest, in Palm Springs.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Palm Springs, CA, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

EōS Fitness
GYM
4.3 on Google · 1379 reviews
4070 Airport Center Dr
Website
Anytime Fitness - Cathedral City, CA
GYM
4.7 on Google · 130 reviews
67555 E Palm Canyon Dr
Website
The Fitness Edge
GYM
4.4 on Google · 128 reviews
170 S Sunrise Way
Website
Crossfit Palm Springs
GYM
5.0 on Google · 127 reviews
1281 N Gene Autry Trail Unit B
Website
Kings Gym
GYM
5.0 on Google · 117 reviews
1281 Gene Autry Trail Ste o
Fit in 42 Personal Training Studio Palm Springs
GYM
4.9 on Google · 89 reviews
68100 Ramon Rd Ste B3 and B4
Website

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Steel Gym
FITNESS
4.3 on Google · 302 reviews
1751 N Sunrise Way
Website
LYV Fitness | Megaformer Training in Palm Springs
FITNESS
5.0 on Google · 124 reviews
1701 N Palm Canyon Dr #8
Website
Forja Strength | Personal Fitness Center
FITNESS
4.8 on Google · 86 reviews
3520 N Anza Rd
Website
SuperSet Gym Personal Training & Fitness Palm Springs
FITNESS
5.0 on Google · 28 reviews
888 E Research Dr Ste 108
Website
Crossfit Palm Springs
GYM
5.0 on Google · 127 reviews
1281 N Gene Autry Trail Unit B
Website
Fit in 42 Personal Training Studio Palm Springs
GYM
4.9 on Google · 89 reviews
68100 Ramon Rd Ste B3 and B4
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Mounjaro cash price (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Mounjaro providers in California

NPI-verified Mounjaro (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Mounjaro in other states

Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]